Increased frequency and suppressive activity of CD127low/- regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement

Immunology

Volumn 140, Issue 3, 2013, Pages 335-343

  Drennan, Samantha ^a   Stafford, Nicholas D ^a   Greenman, John ^b   Green, Victoria L ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

CD127low ; head and neck squamous cell carcinoma; Regulatory T cells; Suppression

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; LYMPH NODE METASTASIS; MALE; PERIPHERAL CIRCULATION; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH;

CD127LOW/-; HEAD AND NECK SQUAMOUS CELL CARCINOMA; REGULATORY T CELLS; SUPPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD4; BLOOD CIRCULATION; CARCINOMA, SQUAMOUS CELL; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; LYMPHATIC METASTASIS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM STAGING; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 84884917924     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12144     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Curado MP, Hashibe M. Recent changes in the epidemiology of head and neck cancer. Curr Opin Oncol 2009; 21:194-200.
3. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363:24-35.
4. Gillison ML, Koch WM, Capone RB et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92:709-20.
5. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002; 8:3137-45.
6. Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002; 8:2553-62.
7. Duray A, Demoulin S, Hubert P, Delvenne P, Saussez S. Immune suppression in head and neck cancers: a review. Clin Dev Immunol 2010; 2010:1-15.
8. Young MRI. Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 2006; 28:462-70.
9. + T regulatory cell-mediated suppression. Immunity 2009; 30:636-45.
10. Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of Treg-mediated T cell suppression. Front Immunol 2012; 3:51.
11. + regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005; 92:913-20.
12. + T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13:6301-11.
13. Chi LJ, Lu HT, Li GL, Wang XM, Su Y, Xu WH, Shen BZ. Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma. Clin Exp Immunol 2010; 161:480-9.
14. + regulatory T cells in patients with hepatocellular carcinoma. Arch Immunol Ther Exp (Warsz) 2011; 59:309-14.
15. low/- regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol 2009; 131:109-18.
16. Wild CA, Brandau S, Lindemann M, Lotfi R, Hoffmann TK, Lang S, Bergmann C. Toll-like Receptors in regulatory T cells of patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2010; 136:1253-9.
17. Mandapathil M, Lang S, Gorelik E, Whiteside TL. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods 2009; 346:55-63.
18. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunological self-tolerance maintained by activated T-cells expressing IL-2 receptor α-chains (CD25) - breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64.
19. + T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193:1295-301.
20. high regulatory cells in human peripheral blood. J Immunol 2001; 167:1245-53.
21. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-61.
22. + regulatory T cells. Nat Immunol 2003; 4:330-6.
23. + T reg cells. J Exp Med 2006; 203:1701-11.
24. Seddiki N, Santner-Nanan B, Martinson J et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203:1693-700.
25. high regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. Head Neck 2011; 33:415-23.
26. Schott AK, Pries R, Wollenberg B. Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer. Int J Mol Med 2010; 26:67-75.
27. Gasparoto TH, Malaspina TSD, Benevides L et al. Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment. Cancer Immunol Immunother 2010; 59:819-28.
28. + regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008; 14:1032-40.
29. + regulatory T cells in gastric cancer. Int J Cancer 2008; 122:2286-93.
30. + effector populations in patients with squamous cell carcinoma of the head and neck. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 2007; 29:120-7.
31. Boucek J, Mrkvan T, Chovanec M et al. Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck. J Cell Mol Med 2010; 14:426-33.
32. high regulatory T cells in nasopharyngeal carcinoma patients. Br J Cancer 2007; 96:617-22.
33. Liotta F, Gacci M, Frosali F et al. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int 2010; 107:1500-6.
34. low/- regulatory T cells in transitional cell carcinoma patients and its significance. J Clin Lab Anal 2009; 23:197-201.
35. Shen XH, Li N, Li H, Zhang T, Wang F, Li QA. Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma. J Cancer Res Clin Oncol 2010; 136:1745-54.
36. lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer 2011; 129:1373-81.
37. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24:1169-77.
38. + regulatory T cells express lower levels of the IL-7 receptor α chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods 2007; 319:41-52.
39. + Tregs and immune control. J Clin Invest 2004; 114:1209-17.